Osteocalcin as a treatment for frailty associated with aging
Methods and compositions for treating frailty in mammals, preferably humans, are provided. The methods generally involve modulation of the OST-PTP signaling pathway or the PTP-1B signaling pathway involving gamma-carboxylase and osteocalcin, e.g., by administration of undercarboxylated/uncarboxylated osteocalcin. The methods comprise alleviating at least one of: muscle wasting or a lung disorder while also alleviating at least one of: a metabolic disorder, a male reproductive disorder, or a cognitive disorder.
1. A method of treating loss of skeletal muscle function, comprising administering to a patient suffering from loss of skeletal muscle function a pharmaceutical composition comprising a therapeutically effective amount of undercarboxylated/uncarboxylated osteocalcin and a pharmaceutically acceptable carrier or excipient,
wherein the undercarboxylated/uncarboxylated osteocalcin is a polypeptide selected from a group consisting of:
(a) a fragment comprising mature human osteocalcin of SEQ ID NO: 12 missing the last 10 amino acids from the C-terminal end,
(b) a fragment comprising mature human osteocalcin of SEQ ID NO: 12 missing the first 10 amino acids from the N-terminal end,
(c) a fragment comprising amino acids 62-90 of SEQ ID NO:2,
(d) a fragment comprising amino acids 1-36 of mature human osteocalcin of SEQ ID NO:12,
(e) a fragment comprising amino acids 13-26 of mature human osteocalcin of SEQ ID NO:12, and
(f) a fragment comprising amino acids 13-46 of mature human osteocalcin of SEQ ID NO:12,
wherein the administering also alleviates asthma.
2. A method of treating loss of skeletal muscle function, comprising:
administering to a patient suffering from loss of skeletal muscle function a pharmaceutical composition comprising a therapeutically effective amount of undercarboxylated/uncarboxylated osteocalcin and a pharmaceutically acceptable carrier or excipient,
wherein the administering also alleviates at least asthma and at least one of a metabolic disorder selected from the group consisting of metabolic syndrome, glucose intolerance, type 1 diabetes, type 2 diabetes, and obesity, a male reproductive disorder selected from the group consisting of low sperm count, impaired sperm motility, impaired sperm viability, low testosterone levels, and excessive apoptosis in testes, or a cognitive disorder selected from the group consisting of anxiety, depression and memory loss.
3. The method of claim 1 , wherein the administering further alleviates a metabolic disorder selected from the group consisting of metabolic syndrome, glucose intolerance, type 1 diabetes, type 2 diabetes, and obesity.
4. The method of claim 1 , wherein the administering further a male reproductive disorder selected from the group consisting of low sperm count, impaired sperm motility, impaired sperm viability, low testosterone levels, and excessive apoptosis in testes.
5. The method of claim 1 , wherein the administering further alleviates a cognitive disorder selected from the group consisting of anxiety, depression and memory loss.
6. The method of claim 1 , wherein the administering further alleviates muscle wasting.
7. The method of claim 1 , wherein the administering further alleviates muscle wasting as well as at least one of a metabolic disorder selected from the group consisting of metabolic syndrome, glucose intolerance, type 1 diabetes, type 2 diabetes, and obesity, a male reproductive disorder selected from the group consisting of low sperm count, impaired sperm motility, impaired sperm viability, low testosterone levels, and excessive apoptosis in testes, or a cognitive disorder selected from the group consisting of anxiety, depression and memory loss.
8. The method of claim 1 , wherein the administering further alleviates muscle wasting as well as a metabolic disorder selected from the group consisting of metabolic syndrome, glucose intolerance, type 1 diabetes, type 2 diabetes, and obesity.
9. The method of claim 1 , wherein the administering further alleviates muscle wasting and a male reproductive disorder selected from the group consisting of low sperm count, impaired sperm motility, impaired sperm viability, low testosterone levels, and excessive apoptosis in testes.
10. The method of claim 1 , wherein the administering further alleviates muscle wasting and a cognitive disorder selected from the group consisting of anxiety, depression and memory loss.
11. The method of claim 1 , wherein the administering further alleviates muscle wasting a metabolic disorder selected from the group consisting of metabolic syndrome, glucose intolerance, type 1 diabetes, type 2 diabetes, and obesity, a male reproductive disorder selected from the group consisting of low sperm count, impaired sperm motility, impaired sperm viability, low testosterone levels, and excessive apoptosis in testes, and a cognitive disorder selected from the group consisting of anxiety, depression and memory loss.
12. The method of claim 1 , wherein the patient is a human who is at least 55 years of age.
13. The method of claim 1 , wherein the osteocalcin is human osteocalcin.
14. The method of claim 13 , wherein the osteocalcin is completely uncarboxylated human osteocalcin.
15. The method of claim 1 , wherein the patient suffers from frailty.
16. The method of claim 1 , wherein the patient suffers from sarcopenia.
17. The method of claim 2 , wherein the cognitive disorder is memory loss due to neurodegeneration.
18. The method of claim 2 , wherein the cognitive disorder is memory loss.
19. The method of claim 18 , wherein the cognitive disorder is at least one of short term memory loss or long term memory loss.
20. The method of claim 2 , wherein the cognitive disorder comprises temporary or permanent loss of an ability to learn, memorize, solve problems, process information, reason correctly, or recall information, and wherein the temporary or permanent loss is at least one of total or partial.
21. The method of claim 2 , wherein the cognitive disorder is anxiety.
22. The method of claim 2 , wherein the cognitive disorder is depression.
23. A method of treating loss of skeletal muscle function, comprising: administering to a patient suffering from loss of skeletal muscle function a pharmaceutical composition which comprises a therapeutically effective amount of undercarboxylated/uncarboxylated osteocalcin and a pharmaceutically acceptable carrier or excipient, wherein the administering also alleviates asthma.
24. The method of claim 23 , wherein the administering improves a distance and/or a time that the patient achieves before exhaustion in an endurance exercise.